Loading
Life sciences · Journal article
Journal of Cancer Metastasis and Treatment · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cellular senescence, a stable state of cell cycle arrest triggered by intrinsic and extrinsic stressors, has emerged as a pivotal regulator of tumor immunity and therapeutic resistance. Senescent cells exhibit pronounced temporal heterogeneity in immune modulation. Early-stage senescence enhances antitumor immunity by increasing immunogenicity and promoting the secretion of pro-inflammatory factors. In contrast, persistent senescence drives an immunosuppressive tumor microenvironment by recruiting myeloid-derived suppressor cells, upregulating immune checkpoints, and propagating a senescent niche. This temporal duality underlies the paradoxical role of therapy-induced senescence in both tumor suppression and immune evasion. Recent advances in senotherapy, including senolytics, senomorphics, and strategies targeting senescent stromal and immune compartments, offer promising avenues to therapeutically exploit senescence. Emerging approaches integrating prodrug designs, targeted protein degradation, and advanced drug delivery systems allow precise, context-specific modulation of senescence, minimizing off-target effects while potentiating immunotherapy. Here, we provide a comprehensive overview of tumor senescence hallmarks, its dynamic crosstalk with immunity, and emerging therapeutic strategies, highlighting current challenges and opportunities for harnessing senescence to overcome immune resistance and enhance cancer immunotherapy.